<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171124037606N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-08</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of autologous platelet-rich plasma on spinal arthrodesis</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effectiveness of autologous PRP in postrolateral arthrodesis of lumbar spine surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-10-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69832</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Blinding description: The outcome evaluators, who are two radiologists, entered their evaluations in separate questionnaires and numerically, and considering that the interventional material is not visible in the imaging, in relation to which side of the patient's spine (right or left) They are completely unaware of the intervention.
The data analyst, who is a statistician, also receives the data numerically and is unaware of which side of the patient's spine (right or left) the intervention took place.</study_design>
      <phase>3</phase>
      <hc_freetext>Postrolateral arthrodesis after lumbar spine fixation.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: On the day of surgery, 26 cc of venous blood was taken from the patient under sterile conditions and placed in 3 special tubes for the preparation of platelet-rich plasma (manufactured by Becton Dickinson) containing 1.5 cc of  Acid Citrate Dextrose (ACD) with a volume of 8.5 cc. are poured and transferred to the laboratory. In the laboratory, platelet-rich plasma is prepared by the double spin method, in this way, first all 3 tubes are placed in a centrifuge (Pars Azma model SH.13) with 1600 rpm for 12 minutes and after finishing the layer work The plasma is separated under sterile conditions and enters the test tube without anticoagulant. Then it is placed again in the centrifuge with 2700 rpm for 5 minutes. After finishing the work, the upper two-thirds of the plasma is separated from the tube and the remaining one-third is gently shaken in a pendulum after a 5-minute rest so that the concentrated platelets merge with the plasma. Then the platelet-rich plasma was transferred to the operating room and at the end of the operation, 2 cc per vertebra in combination with allograft bone (manufactured by Ceno Bone Company) in the posterolateral space on the right or left side of the vertebral column and then the combination of allograft bone with 2 CC of normal saline serum is placed for each vertebra in the posterolateral space on the opposite side of the vertebral column. Then, the patient was followed up for one year with CT scan imaging in the third, sixth and twelfth months after the operation, and the amount of arthrodesis based on the Hounsfield index was numerically calculated in separate questionnaires by two radiologists who did not know about the side of the intervention. will be recorded. Then the average of the reported numbers is delivered to the statistician for statistical calculations. Intervention 2: Control group: the posterolateral space of the vertebral column on the opposite side in the patients of the intervention group, where the combination of 2 cc of normal saline serum is placed for each vertebra along with the bone graft. Then, the patient was followed up for one year with CT scan imaging in the third, sixth and twelfth months after the operation, and the amount of arthrodesis based on the Hounsfield index was numerically calculated in separate questionnaires by two radiologists who did not know about the side of the intervention. will be recorded. Then the average of the reported numbers is delivered to the statistician for statistical calculations.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After de-identifying people, the information about the main outcome will be accessible

When:
The access period starts 6 months after the results are published

To whom:
Researchers working in academic and scientific institutions

Conditions:
For research purposes, descriptive raw data is made available at the discretion of the University Research Committee

Where to obtain:
by Email:
tabibkhooei.a@iums.ac.ir

How to obtain:
After receiving the email about making the information available after checking the qualification of the researcher by the research committee, the information will be sent to the academic email address of the person within a week.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Alireza Tabibkhooei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasool Akram Hospital, Niyayesh Avenue, Sattarkhan Avenue</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6435 2228</telephone>
        <email>tabibkhooei.a@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Alireza Tabibkhooei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasool Akram Hospital, Niyayesh Avenue, Sattarkhan Avenue</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6435 2228</telephone>
        <email>tabibkhooei.a@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with lumbar spine fracture
Patients with lumbar canal stenosis
Patients with lumbar spondylolisthesis</inclusion_criteria>
      <agemin>16 years</agemin>
      <agemax>69 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with a history of spine surgery
Patients suspected of local infection of the spine
Patients with canal stenosis or fractures of cervical and thoracic vertebrae
Patients with malignancy
Patients treated with immunosuppressive drugs
Patients with platelet disorders
Patients with severe osteoporosis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M96.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pseudarthrosis after fusion or arthrodesis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: On the day of surgery, 26 cc of venous blood was taken from the patient under sterile conditions and placed in 3 special tubes for the preparation of platelet-rich plasma (manufactured by Becton Dickinson) containing 1.5 cc of  Acid Citrate Dextrose (ACD) with a volume of 8.5 cc. are poured and transferred to the laboratory. In the laboratory, platelet-rich plasma is prepared by the double spin method, in this way, first all 3 tubes are placed in a centrifuge (Pars Azma model SH.13) with 1600 rpm for 12 minutes and after finishing the layer work The plasma is separated under sterile conditions and enters the test tube without anticoagulant. Then it is placed again in the centrifuge with 2700 rpm for 5 minutes. After finishing the work, the upper two-thirds of the plasma is separated from the tube and the remaining one-third is gently shaken in a pendulum after a 5-minute rest so that the concentrated platelets merge with the plasma. Then the platelet-rich plasma was transferred to the operating room and at the end of the operation, 2 cc per vertebra in combination with allograft bone (manufactured by Ceno Bone Company) in the posterolateral space on the right or left side of the vertebral column and then the combination of allograft bone with 2 CC of normal saline serum is placed for each vertebra in the posterolateral space on the opposite side of the vertebral column. Then, the patient was followed up for one year with CT scan imaging in the third, sixth and twelfth months after the operation, and the amount of arthrodesis based on the Hounsfield index was numerically calculated in separate questionnaires by two radiologists who did not know about the side of the intervention. will be recorded. Then the average of the reported numbers is delivered to the statistician for statistical calculations.</i_keyword>
      <i_keyword>Control group: the posterolateral space of the vertebral column on the opposite side in the patients of the intervention group, where the combination of 2 cc of normal saline serum is placed for each vertebra along with the bone graft. Then, the patient was followed up for one year with CT scan imaging in the third, sixth and twelfth months after the operation, and the amount of arthrodesis based on the Hounsfield index was numerically calculated in separate questionnaires by two radiologists who did not know about the side of the intervention. will be recorded. Then the average of the reported numbers is delivered to the statistician for statistical calculations.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Arthrodesis rate based on Hounsfield index in CT scan images. Timepoint: Evaluation of posterolateral arthrodesis in the third, sixth and twelfth months after surgery. Method of measurement: Helical 16-slice CT scan machine.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-09-26</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat Highway, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
